Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib with Letrozole and Cyclophosphamide in Breast Cancer
NCT00954135Phase 2Unknown
- Sponsor
- University of Turin
- Start
- Sep 2007
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sorafenib in breast cancer (2 arms), sponsored by University of Turin. Primary endpoints: Progression Free Survival at 6 years and Clinical Complete Response Rate. Status: unknown.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00954135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00954135.